Esveidy Isabel Oceguera Nava

Ms. Esveidy Isabel Oceguera Nava

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
EOErfan Oftadeh
Erfan Oftadeh
MBMax Baumann
Max Baumann
MOMarco Ortiz
Marco Ortiz
KMKirubel Mamo
Kirubel Mamo
EBEduam Boeira
Eduam Boeira
BLBruce Lipshutz
Bruce Lipshutz
A new P3N ligand can be prepared quickly in gram quantities, combining PCl3 and n-Bu2NH to arrive at (n-Bu2N)3P, which complexes Pd and is effective for Suzuki–Miyaura and Heck–Cassar–Sonogashira couplings under aqueous micellar conditions.

Verified
Journal Article
Open access
PDF file
SWSitong Wu
Sitong Wu
ENEsveidy Isabel Oceguera Nava
Esveidy Isabel Oceguera Nava
DADennis Ashong
Dennis Ashong
GCGuanglin Chen
Guanglin Chen
QCQiao-Hong Chen
Qiao-Hong Chen
The androgen receptor (AR) signaling pathway is the primary driver of prostate cancer initiation and progression, including the development of castration-resistant prostate cancer (CRPC). Because current AR-targeted therapies inevitably encounter drug resistance, novel strategies to suppress AR signaling are urgently needed. Natural products represent a rich and structurally diverse source of bioactive compounds capable of targeting AR at multiple regulatory levels. This review overviews the interactions between natural products and the AR signaling axis through distinct mechanisms, including inhibition of testosterone production and 5α-reductase activity, direct antagonism of AR, and induction of AR degradation. In addition, several compounds disrupt AR nuclear translocation, downregulate AR splice variants, or suppress AR signaling indirectly through epigenetic regulation, microRNA modulation, or interference with co-regulator networks. Preclinical studies provide compelling evidence that these agents can effectively interrupt AR signaling, thereby suppressing prostate cancer growth. However, challenges remain, particularly the limited pharmacokinetic characterization, lack of in vivo validation, and scarcity of clinical studies. Future research should focus on improving bioavailability, exploring synergistic combinations with existing therapies, and advancing well-designed in vivo and clinical investigations. Collectively, these efforts may establish natural products as lead compounds to modulate AR signaling for prostate cancer prevention and treatment.

20 December 2024 in Molecules
Verified
Journal Article
Open access
PDF file
RDRoxana Gonzalez Dorado
Roxana Gonzalez Dorado
ENEsveidy Isabel Oceguera Nava
Esveidy Isabel Oceguera Nava
GCGuanglin Chen
Guanglin Chen
QZQiang Zhang
Qiang Zhang
GWGuangdi Wang
Guangdi Wang
QCQiao-Hong Chen
Qiao-Hong Chen
Prostate cancer remains a significant global health concern, prompting ongoing exploration of novel therapeutic agents. Licochalcone A, a natural product in the chalcone family isolated from licorice root, is characterized by its enone structure and demonstrates antiproliferative activity in the micromolar range across various cell lines, including prostate cancer. Building on our prior success in enhancing curcumin’s antiproliferative potency by replacing the substituted phenol with a 1-alkyl-1H-imizadol-2-yl moiety, we applied a similar approach to design a new class of licochalcone A-inspired chalcones. The synthesis of these target chalcones involved key [3,3]-sigmatropic rearrangement of aryl prenyl ethers and Claisen–Schmidt condensations, yielding three derivative series. These compounds were evaluated for antiproliferative activity in both androgen receptor (AR)-positive and AR-null prostate cancer cell models using WST-1 cell proliferation assay. Systematic evaluation of licochalcone A across four prostate cancer cell lines indicated a modest advantage over enzalutamide, an FDA-approved AR antagonist, in suppressing 22Rv1 cell proliferation. Interestingly, three ester derivatives by replacing the phenol next to the carbonyl with an alkoxide demonstrated similar antiproliferative potency to licochalcone A in both AR-positive and AR-negative prostate cancer cell lines. This suggests that the phenol moiety on licochalcone A may be a promising site for chemical manipulations to enhance anti-prostate cancer activity. Among the synthesized chalcones, nine derivatives showed improved selectivity for AR-positive LNCaP and 22RV1 cells relative to AR-negative PC-3 and DU145 cells, surpassing licochalcone A in selectivity. Additionally, the antiproliferative potency was highly dependent on the R group attached to the imidazole. Most of the derivatives showed antiproliferative potency against androgen receptor-positive LNCaP and 22Rv1 cells, comparable to that of enzalutamide and licochalcone A. These findings suggest that optimization of licochalcone A-inspired chalcones as potential anti-prostate cancer agents warrants further investigation.

9 July 2025 in Molecules
Verified
Journal Article
Open access
PDF file
SGStan Iridio Gómez
Stan Iridio Gómez
ENEsveidy Isabel Oceguera Nava
Esveidy Isabel Oceguera Nava
ADAbbas Dadawalla
Abbas Dadawalla
DADennis Ashong
Dennis Ashong
GCGuanglin Chen
Guanglin Chen
QCQiao-Hong Chen
Qiao-Hong Chen
Tetracyclic bis-piperidine alkaloids (TcBPAs) are structurally complex natural products primarily isolated from marine sponges of the order Haplosclerida. Distinguished by their intricate architecture, TcBPAs feature two central piperidine units linked by dual macrocyclic rings. These unique structural motifs contribute significantly to their biological activities. For example, TcBPAs exhibit antiproliferative activities at low micromolar concentrations across various cancer cell lines, including leukemia, melanoma, breast, colon, fibrosarcoma, and glioblastoma. Despite this promising therapeutic profile, the structural intricacy of TcBPAs has posed considerable challenges to the development of efficient synthetic methodologies, thereby limiting comprehensive exploration and potential clinical advancement. This review highlights recent progress and persisting challenges in the synthesis, structural analysis, and biological evaluation of TcBPAs, underscoring their therapeutic potential in anticancer drug discovery.